% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Talhouk:156842,
      author       = {A. Talhouk and J. George and C. Wang and T. Budden and T.
                      Z. Tan and D. S. Chiu and S. Kommoss and H. S. Leong and S.
                      Chen and M. P. Intermaggio and B. Gilks and T. M. Nazeran
                      and M. Volchek and W. Elatre and R. C. Bentley and J. Senz
                      and A. Lum and V. Chow and H. Sudderuddin and R. Mackenzie
                      and S. Leung and G. Liu and D. Johnson and B. Chen and A.
                      Ovarian Cancer Study and J. Alsop and S. Banerjee and S.
                      Behrens$^*$ and C. Bodelon and A. H. Brand and L. A. Brinton
                      and M. E. Carney and Y.-E. Chiew and K. L. Cushing-Haugen
                      and C. Cybulski and D. Ennis and S. Fereday and R.
                      Turzanski-Fortner$^*$ and J. García-Donás and A.
                      Gentry-Maharaj and R. Glasspool and T. Goranova and C. S.
                      Greene and P. Haluska and H. R. Harris and J. Hendley and B.
                      Y. Hernandez and E. Herpel and M. Jimenez-Linan and C.
                      Karpinskyj and S. H. Kaufmann and G. Keeney and C. J.
                      Kennedy and M. Köbel and J. Koziak and M. C. Larson and J.
                      Lester and L.-A. Lewsley and J. Lissowska and J. Lubiński
                      and H. Luk and G. Macintyre and S. Mahner and I. A. McNeish
                      and J. Menkiszak and N. Nevins and A. Osorio and O. Oszurek
                      and J. Palacios and S. Hinsley and C. L. Pearce and M. C.
                      Pike and A. Piskorz and I. Ray-Coquard and V. Rhenius and C.
                      Rodríguez-Antona and R. Sharma and M. E. Sherman and D.
                      Silva and N. Singh and H.-P. Sinn and D. J. Slamon and H.
                      Song and H. Steed and E. A. Stronach and P. J. Thompson and
                      A. Tołoczko-Grabarek and B. Trabert and N. Traficante and
                      C.-C. Tseng and M. Widschwendter and L. R. Wilkens and S. J.
                      Winham and B. J. Winterhoff and A. Beeghly-Fadiel and J.
                      Benitez and A. Berchuck and J. D. Brenton and R. Brown and
                      J. Chang-Claude$^*$ and G. Chenevix-Trench and A. DeFazio
                      and P. A. Fasching and M. J. Garcia and S. A. Gayther and M.
                      T. Goodman and J. Gronwald and M. J. Henderson and B. Y.
                      Karlan and L. E. Kelemen and U. Menon and S. Orsulic and P.
                      D. P. Pharoah and N. Wentzensen and A. H. Wu and J.
                      Shildkraut and M. A. Rossing and G. E. Konecny and D. G.
                      Huntsman and R. Y. Huang and E. L. Goode and S. J. Ramus and
                      J. A. Doherty and D. D. L. Bowtell and M. S. Anglesio},
      title        = {{D}evelopment and validation of the gene-expression
                      {P}redictor of high-grade-serous {O}varian carcinoma
                      molecular sub{TYPE} ({P}r{OTYPE}).},
      journal      = {Clinical cancer research},
      volume       = {26},
      number       = {20},
      issn         = {1557-3265},
      address      = {Philadelphia, Pa. [u.a.]},
      publisher    = {AACR},
      reportid     = {DKFZ-2020-01159},
      pages        = {5411-5423},
      year         = {2020},
      note         = {2020 Oct 15;26(20):5411-5423},
      abstract     = {Gene-expression-based molecular subtypes of high-grade
                      serous tubo-ovarian cancer (HGSOC), demonstrated across
                      multiple studies, may provide improved stratification for
                      molecularly targeted trials. However, evaluation of clinical
                      utility has been hindered by non-standardized methods which
                      are not applicable in a clinical setting. We sought to
                      generate a clinical-grade minimal gene-set assay for
                      classification of individual tumor specimens into HGSOC
                      subtypes and confirm previously reported subtype-associated
                      features.Adopting two independent approaches, we derived and
                      internally validated algorithms for subtype prediction using
                      published gene-expression data from 1650 tumors. We applied
                      resulting models to NanoString data on 3829 HGSOCs from the
                      Ovarian Tumor Tissue Analysis Consortium. We further
                      developed, confirmed, and validated a reduced, minimal
                      gene-set predictor, with methods suitable for a single
                      patient setting.Gene-expression data was used to derive the
                      Predictor of high-grade-serous Ovarian carcinoma molecular
                      subTYPE (PrOTYPE) assay. We established a de facto standard
                      as a consensus of two parallel approaches. PrOTYPE subtypes
                      are significantly associated with age, stage, residual
                      disease, tumor infiltrating lymphocytes, and outcome. The
                      locked-down clinical-grade PrOTYPE test includes a model
                      with 55 genes that predicted gene-expression subtype with
                      $>95\%$ accuracy that was maintained in all analytical and
                      biological validations.We validated the PrOTYPE assay
                      following the Institute of Medicine guidelines for the
                      development of omics-based tests. This fully defined and
                      locked-down clinical-grade assay will enable trial design
                      with molecular subtype stratification and allow for
                      objective assessment of the predictive value of HGSOC
                      molecular subtypes in precision medicine applications.},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32554541},
      doi          = {10.1158/1078-0432.CCR-20-0103},
      url          = {https://inrepo02.dkfz.de/record/156842},
}